GSK announced a $10.6 billion acquisition of Nuvalent to secure two experimental lung cancer medicines already under FDA review, marking one of the largest biotech deals in recent years. The move gives the UK firm immediate access to assets with potential approval decisions later this year.

Zoom Out

This deal fits a broader pattern of pharmaceutical giants racing to replenish oncology pipelines amid rising competition and upcoming regulatory milestones. Similar activity includes...